InvestorsHub Logo
Followers 13
Posts 3218
Boards Moderated 0
Alias Born 04/26/2007

Re: None

Wednesday, 01/12/2022 4:13:31 PM

Wednesday, January 12, 2022 4:13:31 PM

Post# of 40503
The GBM INO-5401 trial extension to June 30, 2022 means Ino already had unpublished data for MGMT Methylated Median (cohort B) OS30 = OS24 (95% CI) = 55%, n Alive/N Total = 11/20.

Of course, OS30 data was shared with FDA to obtain trial extension.

MGMT Unmethylated (Cohort A) OS24 (95% CI) = 21.9%, n Alive/N Total = 7/32
OS18% (95% CI) = 50%, n Alive/N Total = 16/32

So, Median OS; unmethylated (A) = 18 months
https://clinicaltrials.gov/ct2/history/NCT03491683?A=31&B=32&C=merged#StudyPageTop
https://s23.q4cdn.com/479936946/files/doc_presentations/INOVIO-Investor-Deck-Presentation_Nov2021.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News